Celtaxsys Announces Results of Phase 2 Trial Showing Clinically Meaningful Improvement in Pulmonary Exacerbations in Cystic Fibrosis Patients

August 2, 2018

Celtaxsys, with continued support from the CF Foundation, has commenced preparations for designing and executing the acebilustat Phase 3 clinical program
More »

Celtaxsys Secures Private Financing to Advance Acebilustat Phase 3 Cystic Fibrosis (CF) Program Preparatory Activities

January 4, 2018

Celtaxsys Secures Private Financing to Advance Acebilustat Phase 3 Cystic Fibrosis (CF) Program Preparatory Activities
More »

Milestone Pharmaceuticals Appoints Lorenz Muller as Chief Commercial Officer

October 24, 2017

Milestone Pharmaceuticals USA, Inc., a clinical stage cardiovascular company, today announced the appointment of Lorenz Muller as Chief Commercial Officer.
More »